Prostate Cancer

Vitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.

Vitaly Margulis, MD, reflects on the secondary end points findings and safety data from the Apa-RP study in high-risk localized prostate cancer.

Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer.

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.

A new radioligand therapy, JNJ-6420, shows promise in treating metastatic castration-resistant prostate cancer with deep and lasting responses after just 1-2 doses.

Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide delays time to progression from mHSPC to mCRPC vs placebo while also increasing overall survival benefit.

A post-hoc analysis showed suspending enzalutamide does not impact quality of life in patients with nonmetastatic hormone-sensitive prostate cancer in the phase 3 EMBARK trial.

Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent prostate cancer, while still improving progression-free survival.

Cabazitaxel plus abiraterone showed improved survival results for patients with previously treated metastatic castration-resistant prostate cancer.

The protocol for a phase 3 clinical trial testing a new combination therapy targeting advanced prostate cancer has received approval from the FDA.

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.

Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.

Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.

Data support using 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.

Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate cancer.

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

In an interview with Targeted Oncology, Kim N. Chi, MD, FRCPC, discussed the MAGNITUDE trial results, including patient-reported outcomes, in patients with BRCA-positive mCRPC.

Neal Shore, MD, FACS, explains how he integrates findings from the ARAMIS trial to inform patient treatment decisions while prioritizing patient values and personal preferences.

Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.

Neal Shore, MD, FACS provides an analysis of the ARAMIS, SPARTAN, and PROSPER trials, which demonstrate improved survival in high-risk non-metastatic castration-resistant prostate cancer through early intervention, highlighting the potential for preventing disease progression based on the data from these pivotal studies.